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The mammalian immune system continually faces death in the form of its own dead and dying cells that arise
during normal tissue turnover, infections, cellular damage, and cancer. Complex decisions must then be
made that will permit a protective response to pathogens, while at the same time destroying tumors but
not attacking vital systems of the host that could lead to autoimmunity. By using an investigative technique
termed the fiveWs (who, what, when, where, and why), we will examine how the immune system responds to
antigens generated via cell death. This analysis will give us a better understanding of the molecular differ-
ences fundamental to tolerogenic or immunogenic cell death, the cells that sense and react to the dead cells,
and the consequences of these fundamental elements on the maintenance or abrogation of tolerance.Introduction
A variety of pathways are used by multicellular organisms to
orchestrate cell death during development and morphogenesis
to control cell numbers and eliminate damaged cells (Penaloza
et al., 2006). It is estimated that up to 106 cells die in the human
body every second, most as a result of normal tissue turnover
(Green et al., 2009). There is also cell death in response to
infection that may represent a primitive defense mechanism
to prevent pathogen replication by removing the infected or
damaged cells. Moreover, the same cell death pathways are
needed to control the number of effector cells generated during
an immune response and then eliminate the majority of them
once the pathogen is cleared (Parish et al., 2009; Pellegrini
et al., 2003; Barreiro et al., 2004). Thus, one of the major chal-
lenges for the immune system is to react to foreign pathogens
within the context of this constant antigenic ‘‘noise’’ derived
from the dead and dying cells, yet not respond to the self-
antigens that can be presented to the immune system in far
greater (and uncontrollable) amounts. Simultaneously, it is
advantageous to retain the ability to direct immune responses
toward the ‘‘self’’ antigens expressed by tumor cells. Thus, the
immune system is faced with the important task of being respon-
sive to pathogens (foreign invaders) while destroying tumors
(derived from self) and not attacking vital systems of the host
(self-antigens).
Understanding how these complex immunological decisions
are made has been intensely investigated over the past 20 years,
although it has been difficult, at times, to get the complete
picture. One reason for this is that each study focused on only
a few criteria that may not apply in every situation. For example,
the general mechanism by which a cell died was proposed to
influence the type of immune response. This concept arose
from some of the original descriptions of apoptosis as being
a ‘‘silent death’’ and tolerogenic, whereas necrosiswas a ‘‘violent
death’’ that released a number of immunostimulatory molecules
(Green et al., 2009; Thompson, 1995). In some instances this has
proven true as demonstrated by studies comparing the tolero-
genic and immunogenic properties of apoptotic and necrotic456 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.cells (Griffith et al., 1996, 2007; Shi et al., 2003). It is now recog-
nized, however, that apoptotic cells can be highly immunogenic,
eliciting protective immune responses (Kepp et al., 2009; Ullrich
et al., 2008; Zitvogel et al., 2004). In an effort to explain this
disparity, some studies have characterized the molecular
composition of dying cells, suggesting that factors released at
the time of cell death could determine the resultant immune
response. For example, the release of cytokines or damage-
associated molecular patterns (DAMPs) from a dying cell can
influence immunity (Bianchi, 2007; Chen et al., 2001; Gao
et al., 1998; Millar et al., 2003). Although these studies are
compelling, the release of factors from dying cells does not
always dictate the type of immune response, because DAMPs
can be modified by the cell death pathway to promote either
tolerance or immunity (Kazama et al., 2008). Another approach
has considered the activation of phagocytic cells as the deciding
factor in the generation of tolerance or immunity to the antigens
associated with the eaten dead cells. These data suggest that
dead cells (apoptotic or necrotic) can inhibit or increase antigen
presentation by the antigen-presenting cell (APC) (Albert et al.,
2001; Dhodapkar et al., 2001; Sauter et al., 2000). However, it
is important to keep in mind that the maturation state of the
phagocyte does not always dictate its ability to induce tolerance
or immunity (Ferguson et al., 2002; Kazama et al., 2008). To
reconcile some of these disparities, the influence of pathogen-
associated molecular patterns (PAMPs) derived from infectious
agents has also been considered, because bacterial products
or viral nucleic acids perceived by phagocytic cells in the pres-
ence of dead cells can dictate the resultant immune response
through activation of APC (Medzhitov and Janeway, 2002;
Torchinsky et al., 2009). This hypothesis, too, has been ques-
tioned by observations where the death of transformed cells
(Obeid et al., 2007) and in some cases nontransformed cells
(Rock and Kono, 2008; Shi et al., 2003) elicited immune
responses in the absence of infection. In addition, debris from
nontransformed cells in some settings can stimulate general
or organ-specific autoimmune responses (Gaipl et al., 2007).
Thus, a simple explanation based on any of these criteria cannot
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As important as it is to consider the factors listed above, it is
equally important to consider those criteria that are not typically
discussed in this context—including variations in the type of
dead cell (e.g., lymphocyte, fibroblast, epithelial cell), cell status
(transformed, nontransformed, activated, naive), immune re-
sponse examined (humoral or cellular), organ or organ system
explored (e.g., gut, eye, skin), availability of T cell help, and
even the desired result (e.g., graft acceptance, antitumor immu-
nity, autoimmunity, immune deviation). With the addition of these
many considerations (and caveats), it becomes even more diffi-
cult to apply general principles to every situation. We certainly
cannot consider all of these variables in this review, but we think
it is important to keep them in mind as we discuss the effects of
cell death on the immune response. Consequently, for our
discussion we have applied (and slightly modified) the old jour-
nalism maxim called the ‘‘five Ws.’’ This is a classical concept
in news style, research, and police investigations such that for
a report to be considered complete it must answer a checklist
of questions—who, what, when, where, why, and how. Thus,
the nature of the immune response that develops in the face of
dead cells depends on who dies, what it releases, when it dies,
where it dies, and why it dies. The answers to these questions
lead us to an understanding of how immunity is regulated. With
these interrogative questions we can perhaps get a better under-
standing of themolecular differences fundamental to tolerogenic
or immunogenic cell death, the cells that sense and react to
the dead cells, and the consequences of these fundamental
elements on the maintenance or abrogation of tolerance. Varia-
tions in these factors can have consequences that range from
effective antipathogen or antitumor immune responses to auto-
immune pathology.
Who Dies: Characteristics of the Dying Cell
Just as different types of living cells are highly specialized to
perform unique functions, the type of cell dying can dramatically
influence the resultant immune response. For example, bortezo-
mib-induced apoptotic myeloma cells expose the chaperone
HSP90 on their surface, facilitating their recognition by dendritic
cells (DCs) and the subsequent induction of immunity (Spisek
et al., 2007). Similarly, in response to some chemotherapeutics
(such as anthracyclins), but not others (such as mitomycin C or
etoposide), tumor cells expose complexes formed by the chap-
erone calreticulin and disulphide isomerase eRp57 on their cell
surface. This occurs at a proapoptotic stage and facilitates the
uptake of dying cells by DCs (Obeid et al., 2007; Panaretakis
et al., 2008). Exposure of these complexes strongly correlates
with immunogenicity, and anthracyclin-treated dying tumor cells
that expose calreticulin can be used as a cancer vaccine.
Because this cell death is caspase dependent and apoptotic,
this is an example where apoptotic death can prime for immu-
nity. In contrast, Ronchetti et al. (1999a, 1999b) found that
although apoptotic tumor cells could prime, they were much
less efficient than nonreplicating live cells. The immunogenicity
of the apoptotic cells was proportional to the number of cells
injected and correlated with the serum concentration of inter-
leukin-10 (IL-10) and interleukin-1 beta (IL-1b). Another study
found that DCs (but not macrophages [Mf]) pulsed with
apoptotic tumor cells were efficient at cross-priming (immunity)(Miyake et al., 2007), highlighting the importance of the cell
phagocytizing the dead cells (see ‘‘Where’’ below). Interestingly,
g-irradiated tumor cells can also be tolerogenic based on their
ability to suppress cytotoxic T lymphocyte (CTL) responses
and antitumor immunity via the induction of CD8+ T cell anergy
and CD4+ regulatory T (Treg) cell responses (Xie et al., 2009).
Thus, apoptotic tumor cells can prime or tolerize depending on
other factors (see ‘‘What’’ below) or the experimental system
(or tumor type) employed. In contrast, a recent study suggests
that in some situations live tumor cells may represent amore effi-
cient method of priming the immune system compared to dead
cells (Matheoud et al., 2010). These authors found that DCs inter-
nalized cytosolic and membrane material into vesicles from
metabolically labeled live cells, leading to enhanced cross-
priming (immunity).
It has been suggested that the death of tissue cells during
normal cell turnover followed by their uptake by resident DCs
is involved in themaintenance of peripheral tolerance (Luckashe-
nak et al., 2008). Several studies have addressed this issue with
systems where model antigens were overexpressed in defined
cells from birth such that they were considered ‘‘self-antigens’’
by the immune system. In these instances, potent tolerance
could be induced to these experimental self-antigens (Adler
et al., 1998; Kurts et al., 1998). Similarly, experiments with non-
transformed cells such as pancreatic islets demonstrate that
apoptotic death canmake these cells efficient tolerogens. Young
nonobese diabetic (NOD) mice injected with a single low dose of
streptozotocin exhibited impaired T cell responses and mice
were protected from spontaneous diabetes. b-cell apoptosis
was necessary for this tolerance, because streptozotocin did
not protect rat insulin promoter-cytokine response modifier A
(RIP-CrmA) transgenic NODmice (Hugues et al., 2002). Similarly,
DCs fed apoptotic islet cells induced potent tolerance and
prevented the development of diabetes in the recipients when
injected (Marin-Gallen et al., 2010). The death of T cells during
activation-induced cell death (AICD) can also induce potent
tolerance, not just by deleting the reactive cells but also by
generating active regulatory cells (Herndon et al., 2005; Gurung
et al., 2010). In this situation, tolerance was directed only to
T cells of the same specificity, perhaps to control potential auto-
immunity during the contraction phase of an immune response
where large numbers of antigen-reactive T cells were deleted.
In a similar manner, treatment of normal mice with intact anti-
body to CD3 (which induces tolerance) increases systemic
TGF-b produced by Mf and immature DC phagocytes exposed
to apoptotic T cells leading to immune suppression (Perruche
et al., 2008). In contrast, in vitro anti-CD3-activated normal
T cells induced to undergo apoptosis are immunogenic, not tol-
erogenic—an effect mediated by CD154 expression on the acti-
vated T cell (Gurung et al., 2009). Similarly, activated g-irradiated
peripheral blood mononuclear cells (PBMC) will mature human
DCs, leading to the production of proinflammatory cytokines
(Johansson et al., 2007). The question then becomes why do
apoptotic T cells in some cases induce tolerance but in others
promote immunity? The answer may lie with the timing of the
T cell death (see ‘‘When’’ below). Perhaps when small numbers
of dying cells arise during normal turnover they are ignored by
the immune system. Regardless, different types of dying cells
can induce dramatically different immune responses, making itImmunity 35, October 28, 2011 ª2011 Elsevier Inc. 457
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are the dying cells releasing as the next important factor.
What It Releases: Tolerogenic and Immunogenic
Factors Produced by Dying Cells
Several mechanisms have been proposed to explain the intrinsic
tolerogenic and immunogenic potential of dead cells, including
the elaboration of cytokines, DAMPs, and other cellular proteins.
Apoptotic lymphocytes produce the immunosuppressive cyto-
kines IL-10 (Gao et al., 1998) and TGF-b (Chen et al., 2001) as
they die. In contrast, DAMPs, such as HMGB1 (Kazama et al.,
2008; Scaffidi et al., 2002), heat shock proteins (e.g., HSP70)
(Millar et al., 2003), uric acid (Shi et al., 2003), mammalian
DNA, RNA, IFN-a (Matzinger, 2002), and CD154 (Gurung et al.,
2009), released by dead cells are immunogenic. Recognition of
DAMPs (e.g., HMGB1) by pattern recognition receptors (PRR)
such as the receptor for advance glycation end products
(RAGE) or toll-like receptors (TLRs) is thought to mature DCs
and stimulate immunity (Bianchi, 2007). In addition, necrotic cells
can activate the inflammasome (immunity), as shown by the
cleavage of caspase 1 and release of mature IL-1b and IL-18
(Lamkanfi and Dixit, 2010; Li et al., 2009). Thus, the different
mechanisms of death along with the production and/or release
of various pro- and anti-inflammatory molecules as a result of
the death process all contribute to whether immunological toler-
ance or immunity is initiated against the antigens associated with
the dead cells.
Interestingly, the release of ‘‘factors’’ is not always predictive
because the cell death process itself can alter the immuno-
genicity of themolecules released. All apoptotic cells can release
DAMPs (Choi et al., 2004; Kazama et al., 2008), but the process
of apoptosis can modify these immunostimulatory molecules to
promote tolerance instead of immunity (Kazama et al., 2008). For
example, intravenously injected necrotic cells promote antigen-
specific immune responses through a mechanism that involves
the release of HMGB1; in the absence of active HMGB1, these
cells induce tolerance. Similarly, apoptotic cells can be immuno-
genic rather than tolerogenic if caspase activation is blocked or
caspase-3 and -7 are absent. This seems to contradict the
requirement for caspase activation in immunogenic cell death
by anthracyclin-treated tumor cells (Zitvogel et al., 2004) (dis-
cussed above), but perhaps factors such as the location of the
dying cells have an effect (see ‘‘Where’’ below). This caspase
requirement was explained by examining the consequences of
caspase activation to the cell. During apoptosis, a loss in mito-
chondrial membrane potential allows for the release of cyto-
chrome c, which further facilitates caspase activation. The active
effector caspases then cleave a component of complex I in the
electron transport chain (NADH dehydrogenase [ubiquinone]
Fe-S protein 1, 75 kDa [NDUFS1]) in the permeabilized mito-
chondria. The resulting inhibition of complex I function induces
the production of reactive oxygen species (ROS) (Ricci et al.,
2004), which oxidizes a key cysteine residue in HMGB1 and
neutralizes its ability to stimulate immunity. Mutation of the
caspase cleavage site in NDUFS1 does not block apoptosis,
but apoptotic cells that express this mutant protein promote
immunity rather than tolerance. Thus, one important factor in
determining whether tolerance or immunity will ensue is whether
HMGB1 (and perhaps other DAMPs) is (are) modified in the dying458 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.cells (Kazama et al., 2008). One prediction would be that during
immunogenic cell death (e.g., after some types of chemotherapy
[Apetoh et al., 2007]), ROS is not produced and DAMPs remain
unmodified; however, this hypothesis remains to be tested. It
is not currently known how HMGB1 modification influences its
ability to bind receptors or other molecules. HMGB1 has been
shown to bind to several cytokines (IL-1b, TNF-a, and IFN-g)
as well as free nucleic acids and the PRR mentioned above
(RAGE, TLR) (Ferguson et al., 2011). It is possible that redox
modification of HMGB1 influences its ability to bind one of these
molecules. However, these data highlight the importance of cas-
pase activation in determining tolerogenicity or immunogenicity.
In support of this it was suggested that caspase-enhanced
presentation could be important for the pathogenesis of human
immunodeficiency virus-1 (HIV-1) because a high frequency of
effector CD8+ T cells that recognize caspase-cleaved epitopes
are in the peripheral blood of HIV-1-infected individuals, and
the frequency of these effector CD8+ T cells correlates with the
frequency of apoptotic CD4+ T cells (Rawson et al., 2007).
Thus, simply considering the factors released from dying cells
is also an inadequate way to predict their tolerogenic or immuno-
genic potential, leading us to consider when a cell dies.
When It Dies: Influence of the Timing of Cell Death
on Tolerance and Immunity
As mentioned earlier, the activation state of the cell when it dies
(especially T cells) can dramatically influence its immunogenicity
or tolerogenicity. Anti-CD3-activated T cells express CD154,
which can change a normally tolerogenic naive apoptotic T cell
into a potent immune stimulator (Gurung et al., 2009). In these
studies, CD154 expression induced DC production of IL-12
and resulted in immunity. This observation contrasts with the tol-
erogenic nature of T cells that undergo AICD (Gurung et al., 2010;
Herndon et al., 2005). Perhaps early during immune activation
the balance between the CD154+ and the CD154– T cells
dictates the fate of the response. For instance, during an acute
infection, the high numbers of CD154-expressing T cells may
help maintain a high threshold of inflammation and immune
responses required to clear the pathogen. However, during
AICD, which occurs toward the conclusion of an immune
response, the T cells may no longer express CD154 and toler-
ance ensues. This permits removal of reactive cells and suppres-
sion of potential anti-self immune responses. Figure 1 is a repre-
sentation of the differential effects of naive versus activated
apoptotic T cells on the immune response. It should be noted
that this tolerance is relatively short lived (60 days) and the
system can then respond to future antigen challenge (Gurung
et al., 2010). It remains to be determined whether immunological
memory occurs in this situation.
Another consideration is the stage of cell death when the
corpses encounter the immune system. Rapid removal of early
apoptotic cells prevents immune stimulation, and failure to
remove dead cells can lead to autoimmunity (Asano et al.,
2004; Hanayama et al., 2004; Ip and Lau, 2004). Apoptotic cells
need to be promptly recognized and cleared to avoid potential
leakage of inflammatory cytoplasmic contents. When dying cells
encounter DCs very early in the cell death process (<2 hr after
induction of apoptosis), they are immunogenic, as are dead cells
that have progressed to late stage apoptosis (>12 hr; a.k.a.
Figure 1. Proposed Mechanism of Tolerance or Immunity Induced by Naive or Activated Apoptotic T Cells
Left: Induction of tolerance by naive apoptotic T cells. Naive apoptotic T cells are taken up by DCs, which remain in an immature state. The antigens derived from
these apoptotic T cells are cross-presented on MHC class I to CD8+ T cells in the absence of costimulatory molecules and CD4+ T cell help. These ‘‘helpless’’
CD8+ T cells upregulate TRAIL expression and then go on to suppress subsequent immune responses mediated by CD4+ T cells. Right: Induction of immunity by
activated apoptotic T cells. CD154-expressing, activated apoptotic T cells activate DCs to upregulate costimulatory molecules (CD80, CD86) and produce
proinflammatory cytokines such as IL-12. Antigens derived from the activated apoptotic T cells are cross-presented on MHC class I and directly presented on
MHCclass II onmatured DCs, resulting in the priming of both CD8+ andCD4+ T cells. Consequently, the proinflammatory cytokines andCD4+ T cell help the CD8+
T cells to fully differentiate into effector CTL instead of a helpless, TRAIL-expressing, CD8+ Treg cells.
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et al., 2002). For optimum tolerogenicity, DCs must encounter
apoptotic corpses approximately 4–8 hr after the induction of
death; presumably this is due to the need for caspase activation,
expression of ‘‘find me and eat me’’ signals, and DAMP modifi-
cation by ROS.
Where It Dies: Influence of the Anatomical Location
of Death on Immunity and Tolerance
Although who, what, and when are important considerations in
our discussion, where the corpses are removed from the body
can directly determine the APC and/or phagocytic cell involved
in stimulating the immune system. Apoptotic cells are typically
phagocytized by Mf and DCs, and apoptotic cells elaborate
a variety of ‘‘find me and eat me’’ signals that direct phagocyte
attraction and engulfment (Green et al., 2009). Phosphatidylser-
ine (PS) present on apoptotic cells play important roles in their
efficient clearance, and a number of cellular receptors expressed
by phagocytes, such as CD36, T cell immunoglobulin domain,
mucin-like domain (Tim)-1, and Tim-4, facilitate the uptake of
apoptotic cells (Miyanishi et al., 2007; Miyasaka et al., 2004;
Peng et al., 2007). Other receptors, including the integrins avb3
and avb5, Class B scavenger receptors, ATP-binding cassette
transporter (ABC1), CD14, receptor tyrosine kinases c-MER,
TYRO, and Axl, CD91 (receptor for heat shock protein gp96),
and signal regulatory protein (SIRP)-a, have also been shown
to play various roles in the recognition and clearance of
apoptotic cells (Peng et al., 2007). A complete discussion of
these molecules is found in an accompanying review (Ravichan-
dran, 2011, this issue) and these issues will not be discussed
further. However, it is clear that the exposure of these molecules
is the result of the cell death process (e.g., caspase activation)
and is critical for apoptotic cell clearance, and that failure to re-
move apoptotic bodies typically leads to inflammation and/orautoimmunity. Indeed, autoimmunity results when Mf uptake
of apoptotic cells is compromised by interfering with specific
‘‘dead cell’’ receptors (e.g., Tim4 or milk fat globule-EGF factor
8 [MFG-E8]). Interestingly, only autoantibodies were induced in
these cases of autoimmunity and anti-self T cell responses
were not detected (Hanayama et al., 2004; Miyanishi et al.,
2007; Miyasaka et al., 2004). This unexpected outcome may
be related to evidence showing that Mf are incapable of
cross-priming despite their profound phagocytic capabilities
(Albert et al., 1998). Thus, it would appear that the consequences
of dead cell phagocytosis on Mf or DCs may be quite different
immunologically.
DCs that engulf apoptotic cells can cross-present self-anti-
gens to T cells and induce tolerance (a.k.a. ‘‘cross-tolerance’’),
such that cross-tolerance has become a central concept in self
tolerance (Albert, 2004). Evidence suggests that several DC
subsets exist that perform different functions depending on their
lineage or regional localization (i.e., where they reside). For
example, splenic CD8a+ DCs promote tolerance whereas
CD8a DCs promote immunity (den Haan et al., 2000). Yet,
CD8a+ DCs are also potent inducers of antiviral immunity (Allan
et al., 2003), and antiviral T cell responses to herpes simplex
virus-1 (HSV-1) infection are more robust when antigens derived
from the infected apoptotic cells are cross-presented on major
histocompatibility complex (MHC) class I rather than when those
antigens are presented by direct infection of the DC (Bosnjak
et al., 2005). Such observations suggest that the location of
the uptake of dying cells, rather than the type of DC, may better
dictate the immunological outcome. For example, CD8a+ DCs in
the skin could promote immunity (cross-priming) because these
cells typically migrate to the regional lymph nodeswhereas these
same DCs that reside in the spleen stimulate tolerance (cross-
tolerance). Interestingly, the spleen is not the only location that
appears to be involved in tolerance induction by dying cells.Immunity 35, October 28, 2011 ª2011 Elsevier Inc. 459
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(Huang et al., 1994), and this organ has also been implicated
as a site for tolerance induction (Crispe et al., 2006).
Although many studies investigating the uptake of apoptotic
cells and their influence on immune function have focused on
Mf (Miyake et al., 2007), DCs can phagocytize apoptotic cells
(Albert et al., 2001) and apoptotic cells can certainly suppress
DC production of proinflammatory cytokines such as IL-12
(Kim et al., 2004). That is why it is essential to consider the region
of the body where the dead cells are engulfed because Mf and
DCs are preferentially concentrated in different anatomical loca-
tions. For example, the absence of splenic marginal zone Mf
delays the clearance of apoptotic cells and promotes immunity
via DC antigen presentation (Miyake et al., 2007), perhaps by
overwhelming immunostimulatory DCs with cellular debris. It is
also well established that antigen-coupled cells injected intrave-
nously induce a state of immune tolerance (Battisto et al., 1980;
Conlon et al., 1980) through a process that involves apoptosis of
the injected cells (Ferguson et al., 2002). However, subcuta-
neous injection of the same cells induces immunity (Greene
and Benacerraf, 1980), and most studies of immunogenic
apoptosis involve injection by this route. Subcutaneous injection
of cells leads to their engulfment by skin-derived DCs that ulti-
mately traffic to LN to induce an immune response. This may
mimic the effect of tumors that are implanted into subcutaneous
sites and undergo apoptosis after chemotherapy (Apetoh et al.,
2007; Chaput et al., 2007).
Although the main player for tolerance or immunity is the DC,
there are no studies (to our knowledge) describing how the
‘‘find me and eat me’’ signals promote DC uptake of dead cells
and then participate in the induction of tolerance or immunity.
In fact, although phagocytosis of dead cells by DCs has been
studied, the requirement for DC phagocytosis via one of the
known PS receptors for tolerance is also largely unexplored.
Deletion of the MFG-E8 receptor in mice results in autoantibody
production but also leads to enhanced CD8+ CTL cross-priming
(i.e., immunity) (PengandElkon, 2011). Thispuzzlingobservation,
aswell as the role of ‘‘findme and eatme’’ signals for tolerance or
immunity mediated through DCs, requires further investigation.
It is also noteworthy that there appears to be a difference in
antigen processing intrinsic to DC subsets that is associated
with increased expression of proteins involved in MHC process-
ing (Dudziak et al., 2007). CD8a+ DCs tend to process antigens
for presentation via MHC class I molecules, whereas CD8a
DCs preferentially present antigens via MHC class II. This
suggests that for tolerance, CD4+ T cell immunity may be dimin-
ished whereas CD8+ T cell immunity is promoted, resulting in
‘‘helpless’’ CTL induction (see below). In one study, CD8a+
DCs preferentially phagocytized apoptotic cells, again suggest-
ing a tolerogenic role for this DC subpopulation (Iyoda et al.,
2002). However, there are other data showing that CD8a+ DCs
are no better at phagocytizing apoptotic cells than are CD8a
DCs (Schnorrer et al., 2006), suggesting that phagocytosis
cannot be the sole criterion for tolerance or immunity.
There are also a number of other consequences for the DC
after an encounter with apoptotic cells that can have implications
for the type of immune response induced. It is generally
accepted that DC maturation through interaction with PAMPs
or DAMPs, asmeasured by increasedMHC class II and costimu-460 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.latory molecule (e.g., CD80, CD86) expression, is critical for the
induction of immunity. Several reports have documented that
apoptotic cells can prevent DCmaturation, keeping them imma-
ture and in a tolerance-inducing state (Albert et al., 2001; Sauter
et al., 2000). This is a compelling idea, but it should be noted that
this is not always the case because mature DCs can also induce
tolerance subsequent to engulfment of apoptotic cells (Ferguson
et al., 2002; Kazama et al., 2008). Thus, simple maturation
cannot be the determining factor and thismay be related to other
factors discussed here such as DC localization (where) and the
properties of apoptotic cells (what).
Why It Dies: Influence of Infection and Tissue Damage
Why cells die can have a strong influence on the subsequent
immune response, especially if the cells are dying as the result
of an infection. Phagocytosis of apoptotic cells in the presence
of TLR ligands (PAMPs) derived from infectious agents can
convert the tolerogenic signals from the apoptotic cells to immu-
nogenic ones by increasing the activation status of phagocytic
cells and changing the inflammatory cytokines they elaborate.
For example, infected apoptotic cells are a critical component
of the innate immune signals instructing Th17 cell differentiation
(Torchinsky et al., 2009), suggesting that pathogens particularly
adept at triggering apoptosis might preferentially induce T cell-
mediated immunity. Similarly, apoptotic vesicles frommycobac-
terial-infected Mf stimulate CD8+ T cell immunity in vivo. In this
system, the apoptotic vesicles displayed potent adjuvant activity
by stimulating protection against M. tuberculosis infection via
TLR (Winau et al., 2006). Likewise, Histoplasma-specific CD8+
T cell immunity could also be induced by DCs that present exo-
genous Histoplasma antigens, either through direct ingestion of
the yeast cells or through uptake of apoptotic Mf-associated
fungal antigens (Lin et al., 2005).
Inflammation and cell death also occur during tissue damage
under sterile conditions, leading to the release of cytoplasmic
contents (i.e., DAMPs) and the activation of immunity. The best
examples of this are the recent studies examining uric acid (Shi
et al., 2003) and ATP release fromdying cells. Uric acid is the final
product of purinemetabolism and its causative role in gout is well
established, because this painful inflammatory condition is the
result of uric acid crystals precipitating in joints and capillaries
(Rock and Kono, 2008). The association between uric acid with
other forms of inflammation and immune regulation was not
apparent until it was found to serve as an adjuvant in CTL
responses against particulate antigens (Shi et al., 2003). Thus,
uric acid released from damaged cells, without an associated
pathogen, can alert the body to danger and stimulate inflamma-
tion. Similarly, the release of nucleotides (including ATP andUTP)
from damaged neurons in mice attracts microglial cells (Mf-like
phagocytes in the brain) to sites of tissue damage (Hanley
et al., 2004; Koizumi et al., 2007). In addition, ATP released
from dying cells is now recognized as an important ‘‘find me’’
signal for phagocytic cells (Elliott et al., 2009). ATPalso stimulates
the inflammasome and in association with TLR ligand stimulation
can result in the release of IL-1b, IL-18, and HMGB1 (Lamkanfi
and Dixit, 2010). Attraction of phagocytic cells and inflamma-
some activation result in the induction of immunity.
It should be noted that the presence of PAMPs (as well
DAMPs) is not always predictive of robust immunity.
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undergo apoptosis (Griffith et al., 1995), but even in the presence
of viral antigens, nucleic acids, and ample DCs for presentation
(McMenamin, 1999; Steptoe et al., 2000), these dead cells
induce systemic immune tolerance to the viral antigens (Griffith
et al., 1996). In this case, apoptosis and tolerance function to
protect the delicate structures of the eye from the damaging
effects of inflammation, thereby preserving vision. Similar tolero-
genic effects of apoptotic cells were observed in an experimental
model of polymicrobial sepsis where sepsis-induced lympho-
cyte apoptosis decreased the survival of the infected host. In
this model, preventing apoptosis via caspase inhibitors or trans-
genic Bcl-2 expression significantly improved survival (Hotch-
kiss et al., 1999a, 1999b, 2000). Further studies revealed that
the presence of infection-induced apoptotic cells also induced
potent immune tolerance for a subsequent T cell response
(Unsinger et al., 2010). Thus, it would seem that the immunosti-
mulatory potential of the PAMPs elicited by the infection can be
overcome by the presence of large numbers of apoptotic cells.
This could be considered a detrimental effect of apoptotic cell-
induced tolerance because immunosuppressed septic patients
are prone to secondary nosocomial infections (Hotchkiss et al.,
1999b).
How Is Immunity Regulated: A Synthesis of the Five Ws
The immune system has devised multiple means by which
immunological tolerance is maintained. Thymic selection re-
moves the vast majority of developing thymocytes that express
a TCR with high specificity for self-peptide:MHC complexes,
but some self-reactive T cells still make it through the selection
process (Sprent and Kishimoto, 2002). The elimination of periph-
eral cells capable of responding to self-antigens or antigens
associatedwith apoptotic cells is onemeans bywhich peripheral
tolerance can be established, with FasL-dependent AICD and
Bim-mediated death being key pathways of establishing and/
or maintaining peripheral tolerance (Green et al., 2003; Hildeman
et al., 2002; Pellegrini et al., 2003). The timely elimination of
lymphocytes—especially those immune cells that can respond
to self-antigen—is one way to prevent their accumulation and
persistence. Autoimmune lymphoproliferative syndrome (ALPS)
exemplifies how disruption of the Fas signaling pathway leads
to the massive accumulation of autoreactive lymphocytes that
would normally be eliminated via deletion and the development
of a variety of autoimmune pathologies (Straus et al., 1999).
Onewould expect, though, that tolerance resulting from lympho-
cyte deletion would be transient because the deleted cells
should eventually be replenished. Indeed, deletional tolerance
wanes over time, as seen in models of soluble peptide antigen-
induced peripheral T cell deletion, but the process of T cell
expansion and contraction after the injection of soluble peptide
antigen also generates Treg cells that can maintain tolerance
for an extended period—even after a second infusion of antigen-
specific effector T cells (Gurung et al., 2010; Herndon et al.,
2005).
Work by Gershon and Kondo (1970, 1971) pioneered the idea
that immune tolerance was actively mediated by regulatory
or suppressive populations of T cells that could also transfer
tolerance to a naive individual (termed ‘‘infectious immunologic
tolerance’’). Interestingly, the immune cells responsible for trans-ferring immunologic tolerance in these studies were CD8+ T cells
(Cantor et al., 1976; Gershon et al., 1972); however, the inability
to successfully isolate and identify these CD8+ Treg cells led to
skepticism about their true existence despite the consistent
reproducible observation of the suppressive activity of these
cells. The description of CD4+CD25+Foxp3+ Treg cells in the
1990s revived the idea that T cells are potent regulators of immu-
nity (Takahashi et al., 1998). There have been numerous reports
describing the basic characteristics of CD4+CD25+Foxp3+ Treg
cells, and immune regulation by Treg cells has been implicated in
numerous experimental model systems, including transplanta-
tion and autoimmunity (reviewed in Rudensky, 2011; Sakaguchi
et al., 2006). Apoptotic cell infusion or the in vivo depletion of
T cells via CD3-specific mAb results in the expansion of
CD4+CD25+Foxp3+ Treg cells associated with the production
of TGF-b from Mf and DCs that phagocytize the apoptotic cells
(Kleinclauss et al., 2006; Perruche et al., 2008). The increase
in CD4+CD25+Foxp3+ Treg cells in this system is also related
to the selective depletion of CD4+Foxp3 conventional T cells
(Penaranda et al., 2011). In contrast, the recognition of apoptotic
cells in the context of inflammation can direct helper T cell differ-
entiation in a very different direction that supports productive
(and sometimes pathogenic) immunity. Specifically, phago-
cytosis of bacterially infected apoptotic cells (i.e., TLR ligand-
expressing apoptotic cells) drives IL-6, IL-23, and TGF-b produc-
tion by DCs leading to the induction of Th17 cells. Blocking
apoptosis prevents the development of a Th17 cell-mediated
immune response needed to clear the infection (Torchinsky
et al., 2009). This finding is very important when one considers
that self-reactive Th17 cells are prominent players in a number
of autoimmune diseases (Hu et al., 2011; Ja¨ger and Kuchroo,
2010), making it tempting to speculate that the autoimmunity
was triggered by substantial apoptotic death during a time of
infection or inflammation. This contrasts the tolerogenic effects
of ‘‘substantial’’ apoptosis during sepsis (Hotchkiss et al.,
1999b; Unsinger et al., 2010), indicating that further study of
these mechanisms is required.
DCs can cross-present antigens associated with apoptotic
cells by MHC class I molecules to CD8+ T cells (cross-priming)
(Albert et al., 1998). Perhaps paradoxically, the induction of toler-
ance by apoptotic cells also depends on MHC class I and can
involve the deletion of CD8+ T cells as well as immune suppres-
sion by CD8+ Treg cells (cross-tolerance) (Ferguson et al., 2002;
Heath and Carbone, 2001; Steinman et al., 2003). Reconciling
cross-priming and cross-tolerance provides insights into one
mechanism of immunity or tolerance induction by dying cells.
After antigen recognition by CD8+ T cells and their development
into CTL, the long-term fate of these cells is determined by addi-
tional signals provided by DCs, which must be ‘‘licensed’’ by
a previous CD40-CD154-mediated interaction with activated
CD4+ T cells (Schoenberger et al., 1998). Without this additional
signal, the activated helpless CTL function as primary effector
T cells but with a short lifespan (Sun and Bevan, 2003) or they
die as a result of AICD after subsequent exposure to antigen
(Janssen et al., 2005, 2006). AICD in this instance is mediated
by TNF-related apoptosis-inducing ligand (TRAIL), which trig-
gers apoptosis in the helpless CTL and other activated T cells.
The relationship between these observations and the induction
of tolerance (cross-tolerance) by apoptotic cells became clearImmunity 35, October 28, 2011 ª2011 Elsevier Inc. 461
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engulfed necrotic cells could present antigen to both CD4+ and
CD8+ T cells, but those that engulfed apoptotic cells presented
antigen only to CD8+ T cells (Griffith et al., 2007). Consequently,
the CD8+ T cells produced TRAIL after re-exposure to antigen,
which inhibited the induction of a cell-mediated immune
response mediated by CD4+ T cells—a phenomenon we have
noted in other experimental models of tolerance (Griffith et al.,
2011; Gurung et al., 2010). Thus, exposure of the immune system
to apoptotic cells can shift the development of classical ‘‘helped’’
CTL-mediated immune responses to those dominated by tolero-
genic, helpless CTL that produce TRAIL after re-exposure to
antigen (see Figure 1). Although one effect of apoptotic cells
on DC function is to prevent activation of CD4+ T cell help for
CTL, in some cases DCs that have engulfed apoptotic cells can
drive CD4+ T cell differentiation toward the Th2 cell type via the
production of IL-10 (Gao et al., 1998). We do not know whether
such Th2 cells can license DCs to promote CD8+ T cell immunity,
but if not, suchpolarizationmay further promote thegeneration of
helpless CD8+ T cells to suppress immune responses.
Can This Information Be Exploited for Therapeutic
Purposes?
One of the most important considerations subsequent to our
discussion of the five Ws is how can we take what we have
learned to date and apply it therapeutically. In some cases, it
will be critical to break the tolerance induced by the apoptotic
cells to restore immunity. One recent example that fits this
concept used the mouse model of sepsis induced by cecal liga-
tion and puncture, which leads to the induction of tolerance, but
also included a secondary heterologous bacterial infection
subsequent to sepsis initiation. Septic mice had a reduced ability
to control the secondary infection, which was paralleled by sup-
pressed T cell responses, versus sham-treated control mice.
Administration of a blocking TRAIL mAb to the septic WT mice
restored the ability to control the secondary infection and
generate Ag-specific CD8+ T cell responses like those seen in
sham-treated mice (Gurung et al., 2011). A second example is
the use of apoptotic tumor cells in cancer vaccines, which is
becoming more accepted as a viable immunotherapy option in
some cancer patients. The GVAX platform of cancer immuno-
therapy utilizes a vaccine consisting of irradiated whole tumor
cells that have been modified to secrete granulocyte macro-
phage-colony stimulating factor (GM-CSF), which helps recruit
and mature the APC that phagocytize the injected apoptotic
tumor cells (Hege et al., 2006).
It may also be desirable to use apoptotic cells to deliberately
establish tolerance. Organ transplantation has long appreciated
the powerful tolerogenic potential of apoptotic cells (Kleinclauss
et al., 2003, 2006; Li et al., 2006; Morelli and Larregina, 2010),
and it is clear that the alterations in APC function and the gener-
ation of regulatory cells occurs in transplant recipients given an
infusion of apoptotic cells therapeutically. The use of apoptotic
cells to prevent autoimmunity has also been reported. Specifi-
cally, intravenous injection of myelin oligodendroglial glycopro-
tein (MOG)-expressing apoptotic cells reduced MOG-specific
T cell responses and prevented the development of experi-
mental autoimmune encephalomyelitis (EAE) (Miyake et al.,
2007). Similar results were found in another model of experimen-462 Immunity 35, October 28, 2011 ª2011 Elsevier Inc.tally induced disease (Smith and Miller, 2006). The therapeutic
use of apoptotic cells in this fashion is very exciting, but it is
important to remember that the apoptotic cells were given
prophylactically (prior to the induction of EAE), and it remains
to be seen whether the same therapeutic benefit would be
seen in settings where autoimmunity was already established.
Extracorporeal photopheresis has been used clinically for
almost 20 years as an approved therapy for the treatment of
cutaneous T cell lymphoma (Dupont and Craciun, 2009). For
this treatment, peripheral blood is treated ex vivo with a photo-
activatable compound (8-methoxypsoralen) and UVA light and
immediately returned to the patient. A similar strategy is being
tested for the treatment of graft-versus-host disease (Hannani
et al., 2010). Although mechanisms are not completely clear,
tolerance is thought to be the result of apoptosis in the treated
leukocytes followed by uptake by the patient’s phagocytes
leading to modulation of the immune response and decreased
severity of the disease.
Another area of potential therapeutic intervention is related
to the recent findings with HMGB1 in which the redox status
of the protein determines its immunogenicity. When HMGB1 is
released from apoptotic cells, it is oxidized and tolerance to
antigen associated with the apoptotic cells develops. In con-
trast, when HMGB1 was reduced by treatment of the apoptotic
cells with antioxidants or when a form of HMGB1 was used
that could not be oxidized (changing HMGB1 Cys106 to Ser),
it promoted immunity to the same antigen (see above discussion
and Kazama et al., 2008). BecauseHMGB1 is thought tomediate
inflammation in a number of pathogenic processes including
septic shock (Bianchi, 2007), perhaps this is related to its redox
status. The oxidative conditions generated during sepsis (Roth
et al., 2004) may oxidize HMGB1 such that in the presence of
apoptotic cells, tolerance ensues. Thus, treatment of immuno-
suppressed individuals with a nonoxidizable form of HMGB1
might be a method to overcome the immunosuppression in-
duced by apoptotic cells promoting beneficial adaptive immune
responses.
Concluding Thoughts
It is safe to say that in all aspects of life, organisms must deal
with death. Although there is no immunological consequence
associated with death at the end of life, from birth our immune
systems must deal with continuous exposure to dying and
dead cells. Therefore, understanding how the mammalian
immune system deals with the myriad of antigens associated
with dying and dead cells can have important implications for
the study of cancer biology, infectious diseases, tissue injury,
and autoimmunity. At this point we have to ask ourselves
why the effects of cell death on the immune system are
so complex. When the complexity of the vertebrate immune
system was increased to deal with pathogens, it also increased
the chances of eliciting autoimmune reactions (Green et al.,
2009). Failing (or delaying) to remove dying cells can be highly
inflammatory and activate autoimmunity, but the mechanisms
of dead cell removal are highly conserved in animals with
no adaptive immune system. Because pathogens evolved in
parallel to avoid detection, the immune system once again
adapted to deal with these invaders by incorporating the more
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Figure 2. Predicting the Immunological
Outcome via the Five Ws
Each petal represents one of the five Ws and
contains some of the factors considered in this
review. The color gradient indicates a spectrum
from tolerogenic (blue) to immunogenic (red). It is
important to note that any element in a particular
petal may be linked to any element in the other
petals, resulting in a very large number of poten-
tial permutations. For example, a resting (when)
lymphocyte (who) induced to die during sepsis
(why) releases IL-10 (what) and is then engulfed
by a splenic CD8a+ DC (where) and will induce
immune tolerance via a helpless CD8+ T cell
that makes TRAIL (how). Also consider another
example: an apoptotic (when) normal tissue cell
(who) infected with a virus (why) releases reduced
HMGB1 (what) as it dies. The infected apoptotic
cell is then engulfed by a CD8a+ DC in the skin
(where), leading to cross-priming and activation
of virus-specific CTL-mediated immunity (how).
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Reviewimmune response (Medzhitov and Janeway, 2002). However,
dead cells cannot always be immunogenic because this might
lead to autoimmunity, and they certainly cannot always be tol-
erogenic because thismight prevent adaptive responses against
the invaders. Thus, the immune system is constantly evaluating
cell death based on many of the criteria discussed here to stay
ahead of infectious agents, promoting survival of the organism.
To better understand the issues involved in determining the
immunogenic or tolerogenic nature of dead cells, we have
applied the investigative technique called the five Ws. With this
formula we have tried to get the ‘‘full story’’ to help us predict
the outcome of the encounter between dead cells and the
immune system. The principle underlying the maxim is that
each question should elicit a factual answer, and importantly
none of these questions can be answered with a simple ‘‘yes’’
or ‘‘no.’’ The result of an encounter between dead cells and the
immune system depends on factors related to who dies, what
it releases, when it dies, where it dies, and why it dies to collec-
tively determine how immunity is regulated. Figure 2 is our inter-
pretation of a fiveWs flower petal diagram commonly used in this
analysis. We hope this diagram can make some sense out of the
complexities involved by determining the contribution of each
petal (the five Ws) and applying the result to the immuneImmunity 35,response (how). Because of space limita-
tions, we have limited our discussion
to the effects of cell death on T cell
responses; however, we hope that these
ideas can be applied to understating the
nature of B cell response and factors
that induce B cell tolerance. Although
we probably don’t have enough informa-
tion to be precise in every case, we can
keep these in mind as we continue to
study this important area of immunology.
We are reminded of Mark Twain’s
comment on naming constellations in
Following the Equator: A Journey Around
the World (1897): ‘‘Constellations have
always been troublesome things toname. If you give one of them a fanciful name, it will always refuse
to live up to it; it will always persist in not resembling the thing it
has been named for.’’ Hopefully with more study, we can be
more precise in determining the constellation of immunological
responses in the presence of cell death.
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